In-vitro Characterization of Solrikitug, A Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab
作者
K. Komori,Michael Lore,H. Postlethwaite,Volkan Manga,Lisa Wittmer,Hector G. Ortega
Abstract Introduction: Thymic stromal lymphopoietin (TSLP) is an alarmin expressed by epithelial cells in the lung, skin and gastrointestinal tract upon inflammation and tissue damage. As an upstream initiator of inflammatory cascades, TSLP activates dendritic and mast cells, and promotes Type 2 inflammation. Solrikitug is a fully humanized anti-TSLP monoclonal antibody in development for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis. To understand potential advantages compared to tezepelumab, head-to-head in vitro studies assessing binding affinity, epitope identification, and functional inhibition were performed. Methods: Solrikitug and tezepelumab binding affinities, on-rates, and off-rates, were determined by surface plasmon resonance. Competitive TSLP binding was assessed by biolayer interferometry with sequential antibody binding to TSLP. Functional inhibition was evaluated by TSLP-dependent proliferation of Ba/F3 cells, and assessment of TARC expression by ELISA following stimulation of healthy volunteer PBMC with TSLP for 5 days. Results: Solrikitug and tezepelumab bind to TSLP with similar affinities (11 pM vs. 16 pM, respectively), on-rates and off-rates. Competitive binding assays demonstrated that solrikitug and tezepelumab did not compete with each other for TSLP binding, indicating the two antibodies recognize different epitopes on TSLP. Solrikitug was a more potent inhibitor of TSLP-dependent cell proliferation and TARC expression compared to tezepelumab. Conclusions: Solrikitug is a potent anti-TSLP monoclonal antibody in development for the treatment of respiratory and gastrointestinal inflammatory diseases. Solrikitug demonstrates unique epitope binding compared to the approved in class comparator, tezepelumab. Moreover, solrikitug demonstrates potentially best-in-class functional inhibition. The differentiated profile of solrikitug compared to tezepelumab supports the potential of solrikitug for the treatment of patients with severe respiratory conditions such as asthma and COPD.